The results indicate that ARL4C could be a “switch” between the EGFR path and the JAK2/STAT5/β-catenin path to maintain the proliferation, migration, and invasion of cancer cells when cells are exposed to Erlotinib and EGFR path is blocked. This evidence concerns the gene ARL4C and cancer.